DEF 14A: QuidelOrtho Outlines 2025 Annual Meeting Agenda, Including Director Elections and Equity Incentive Plan Approval

QuidelOrtho's proxy statement details proposals for the 2025 annual meeting, including the election of directors, approval of an equity incentive plan, and ratification of the independent auditor.

Summary

• QuidelOrtho has released its proxy statement for the 2025 Annual Meeting of Stockholders, scheduled for May 20, 2025.
• The meeting will be held virtually.
• Stockholders will vote on several key proposals, including the election of 11 director nominees.
• A proposal to approve the adoption of QuidelOrtho's Second Amended and Restated 2018 Equity Incentive Plan is also on the agenda.
• Additionally, stockholders will cast an advisory vote on executive compensation and ratify the selection of KPMG LLP as the independent auditor for the fiscal year ending December 28, 2025.
• The Board recommends voting FOR all director nominees, the Equity Incentive Plan Proposal, the Say-on-Pay Proposal, and the External Auditor Proposal.
• The Notice of Materials and related proxy materials were first made available to stockholders on or about April 8, 2025.
• The company is seeking approval to increase the number of shares authorized for issuance under the 2018 Equity Incentive Plan by 6,200,000 shares, bringing the total to 9,350,000 shares.
• The proposal also seeks to extend the term of the 2018 Plan from May 15, 2028, to May 20, 2035.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, outlining the agenda and proposals for the annual meeting. While there are some mentions of past performance and future expectations, the overall tone is neutral and factual. The sentiment is slightly positive due to the company's efforts to engage with investors and implement sound governance practices.

Positives

• The Board is actively engaged with investors to discuss strategy, performance, governance, and compensation.
• The company has a clawback policy in place to recover compensation in certain circumstances.
• The company has stock ownership guidelines for directors and officers to align their interests with those of stockholders.
• The company is committed to sustainability matters and has published a 2023 Sustainability Report.
• The company is using a greater percentage of performance-based equity awards to incentivize our CEO and other senior executive officers to achieve certain Company performance goals.

Negatives

• Ernst & Young's report noted that the Company identified material weaknesses related to (1) revenue, accounts receivable and accrued rebates due to undue reliance on information generated from certain software solutions and design and operating deficiencies related to management review controls, and (2) insufficient controls over the evaluation of all available evidence to assess realizability of deferred tax assets.
• During 2024, the Compensation Committee granted stock option awards to Ms. Hodges and Mr. Klein within the period beginning four business days before our filing or furnishing of a current report on Form 8-K that disclosed material nonpublic information (other than a current report on Form 8-K disclosing a material new stock option award under Item 5.02(e) of such Form 8-K), and ending one business day after the filing or furnishing of such report.

Risks

• The company's future performance and ability to achieve its goals are subject to various risks and uncertainties.
• The company's compensation programs may not always align with stockholder interests or achieve desired outcomes.
• The company's ability to attract and retain qualified personnel is subject to competitive pressures.
• The company's business is subject to regulatory and legal risks.
• The company's business is subject to cybersecurity and data privacy risks.

Future Outlook

The company expects cost-savings initiatives implemented in 2024 to improve operating effectiveness and deliver incremental margin improvement in 2025 and beyond.

Industry Context

The document provides insight into QuidelOrtho's corporate governance practices, executive compensation strategies, and financial performance, which can be compared to industry peers to assess its competitiveness and alignment with market standards.

Comparison to Industry Standards

• The document references a peer group of publicly-traded biotechnology, healthcare equipment, healthcare supplies and life sciences tools and services companies, including Align Technology, Masimo Corporation, and Hologic, Inc.
• Executive compensation practices are benchmarked against this peer group to ensure competitiveness.
• The company's stock ownership guidelines for directors and officers are designed to align their interests with those of stockholders, a common practice among publicly traded companies.
• The company's clawback policy is intended to comply with Nasdaq listing rules and promote accountability, reflecting a commitment to corporate governance best practices.

Management Changes

Corporate Governance

Legal Proceedings

• The document references shareholder derivative lawsuits involving certain current and former executive officers and members of the Board, with details available in Note 14 of the Consolidated Financial Statements in the Annual Report.

Related Party Transactions

• In May 2022, QuidelOrtho, Quidel, and Ortho entered into a Principal Stockholders Agreement with Carlyle Partners VI Cayman Holdings, L.P., a beneficial owner of more than 5% of our Common Stock as of such date.
• On November 21, 2024, the Carlyle Stockholder completed its sale of all shares of our Common Stock held by it in a registered underwritten offering for approximately $291.7 million, and as a result, the Stockholders Agreement terminated pursuant to its terms.

Stakeholder Impact

• Approval of the equity incentive plan is intended to benefit stockholders by aligning employee and director interests with long-term value creation.
• The company's commitment to sustainability and ethical practices is intended to positively impact communities and stakeholders.
• Changes in executive compensation and leadership may impact employee morale and productivity.
• The selection of an independent auditor is intended to ensure the integrity of financial reporting and protect investor interests.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote on the proposals.
• The company will hold the 2025 Annual Meeting of Stockholders on May 20, 2025.
• The company will file a registration statement on Form S-8 with the SEC covering the new shares reserved for issuance under the Second A&R 2018 Plan in the second quarter of fiscal year 2025.

Key Dates

Keywords

proxy statement, annual meeting, directors, equity incentive plan, executive compensation, KPMG, governance, stockholders, audit committee, compensation, QuidelOrtho